Literature DB >> 24583981

Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?

Detlef Schlöndorff1.   

Abstract

A soluble proteinuric substance has been postulated as a cause of primary focal segmental glomerulosclerosis (FSGS), and one candidate soluble urokinase receptor (suPAR). Evaluation of published results shows that serum suPAR determinations by current methodology do not reliably distinguish FSGS from other proteinuric glomerular diseases and serum suPAR cannot currently be considered a valid biomarker for primary or secondary FSGS. However, this should not discourage further research on potential roles of suPAR in proteinuric renal disease, including FSGS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24583981     DOI: 10.1038/ki.2013.549

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  17 in total

1.  The hype cycle for soluble urokinase receptor in FSGS: passing the trough of disillusionment?

Authors:  Björn Meijers; Ben Sprangers
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-15       Impact factor: 8.237

2.  suPAR is the circulating factor in some but not all FSGS.

Authors:  Howard Trachtman; Jochen Reiser
Journal:  Nat Rev Nephrol       Date:  2014-08-26       Impact factor: 28.314

3.  Glomerular disease: The search goes on: suPAR is not the elusive FSGS factor.

Authors:  Jeroen K Deegens; Jack F Wetzels
Journal:  Nat Rev Nephrol       Date:  2014-06-24       Impact factor: 28.314

4.  Soluble urokinase-type plasminogen activator receptor in FSGS: stirred but not shaken.

Authors:  Jochen Reiser; Harold Chapman
Journal:  J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 10.121

5.  Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.

Authors:  Oliver Staeck; Torsten Slowinski; Ina Lieker; Kaiyin Wu; Birgit Rudolph; Danilo Schmidt; Susanne Brakemeier; Hans-Hellmut Neumayer; Changli Wei; Jochen Reiser; Klemens Budde; Fabian Halleck; Dmytro Khadzhynov
Journal:  Transplantation       Date:  2015-12       Impact factor: 4.939

Review 6.  Podocyte-actin dynamics in health and disease.

Authors:  Luca Perico; Sara Conti; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

7.  Nephronectin (NPNT) and the prediction of nephrotic syndrome response to steroid treatment.

Authors:  Mona Mohamed Watany; Hemat El-Sayed El-Horany
Journal:  Eur J Hum Genet       Date:  2018-06-11       Impact factor: 4.246

8.  A case report of adrenocorticotropic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring.

Authors:  Siddiq Anwar; Derek S Larson; Nima Naimi; Muhammad Ashraf; Nancy Culiberk; Helen Liapis; Changli Wei; Jochen Reiser; Daniel C Brennan
Journal:  Front Med (Lausanne)       Date:  2015-03-20

Review 9.  Biomarkers in pediatric glomerulonephritis and nephrotic syndrome.

Authors:  Gabriel Cara-Fuentes; William E Smoyer
Journal:  Pediatr Nephrol       Date:  2021-01-03       Impact factor: 3.714

10.  suPAR and Team Nephrology.

Authors:  Howard Trachtman
Journal:  BMC Med       Date:  2014-05-20       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.